Endocrine Abstracts

Long-acting somatostatin receptor ligands (LA-SRLs) are a first line medical treatment for acromegaly but require monthly parenteral administration. Paltusotine (CRN00808) is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability (70%), suitable for once daily, oral dosing. The recently reported results of the ACROBAT Edge study (NCT03789656) suggest that patients with acromegaly treated with injected SRLs can switch to once dai...

IntroductionLithium remains a first-line treatment for several mental disorders.Hypercalcaemia has been associated with long-term lithium treatment, yet it is often unrecognized. The manifestations of hypercalcaemia can develop insidiously and mimic psychiatric disturbances.CasesCase Report 1 – A 53-year-old Caucasian gentlemen referred by his GP following routine bloods with an adjusted calcium of 3.46 ...

Laboratory skills are a critical part of science education, enabling students to develop practical competencies and to relate theoretical learning to the laboratory bench. However, practical learning is often daunting for students, particularly those making the transition from secondary school to higher education. To support this transition, we have developed ‘The Biomedical Kitchen’, which introduces first year Medical Biosciences students to laboratory practice thr...

Background: Paltusotine is an investigational oral, once-daily, small molecule somatostatin receptor type 2 agonist in development for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.Methods: This multicenter, open-label, phase 1 study enrolled participants with mild, moderate, and severe hepatic impairment based on Child-Pugh classification and matched healthy participants. A single 20-mg oral dose of paltusotine...

Background: G3NETs demonstrate variable clinical behavior (Ki-67>20-100%). Treatment extrapolated from grade 1/2 (G1/2) NETs and neuroendocrine carcinomas depending on clinicopathologic features. Therapy for treatment-emergent G3NETs remains especially ill-defined.Methods: Retrospective chart review of patients with de novo G3NETs or progressing from low-to-high grade (L-H) (G1/2 at diagnosis and G3 >=3 months later). Treatment patterns compared ...

Background: Serotonin produced by ileum neuroendocrine tumors (i-NETs) promotes development of the mesenteric mass (MM) associated with lymph node metastases. We previously reported that more extensive MM progression along the superior mesenteric vessels predicts a lower rate of complete surgical resection. In this study, we hypothesized that tumoral serotonin production is associated not only with the development of MM but also its progression, and we examined serotonin level...

Background: Serotonin production by ileum neuroendocrine tumors (i-NETs) is considered a critical mediator of the fibrotic reaction in mesenteric mass (MM)/ lymph node metastasis. Antidepressants modify serotonin dynamics: however, their role in MM formation is uncertain. We hypothesized that histories of antidepressant use affect MM formation. This study examined the correlation between antidepressant use and MM formation.Methods: One hundred eighty-two...

Background: Carcinoid syndrome (CS), the most common functional neuroendocrine tumor (NET) syndrome, is characterized by watery diarrhea or cutaneous flushing. While somatostatin receptor ligand (SRL) depot injections are mainstay treatments for CS, discomfort with injections and inadequate symptom relief at labeled doses are seen with many patients. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS...

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

Background: Neuroendocrine tumours of the appendix (ANET) are relatively indolent tumours typically identified incidentally at surgery for suspected appendicitis. The role of right hemicolectomy (RH) for tumours with ‘high risk’ features is debated. We compared the management of ANET at three centres against ENETS criteria for therapy selection.Methods: Retrospective review of all patients diagnosed with ANET at three tertiary centres. Patients...